For decades, graphene has been hailed as a material poised to revolutionize multiple industries. With unparalleled strength, electrical conductivity, and flexibility, it holds immense potential to transform semiconductors, energy storage, and biomedical devices. However, despite its promise, graphene’s full impact remains unrealized—hindered by fundamental challenges in scalable, ultra-high-quality production. Commercially available graphene includes defects, contamination, and damage, preventing graphene from meeting the stringent demands of high-performance applications. At the same time, cryogenic electron microscopy (cryo-EM)—a groundbreaking tool for disease research and drug discovery—is constrained by poor-quality sample grids. These limitations prevent researchers from capturing clear, high-resolution images of biological molecules, slowing advancements in medical science. Graphene-based grids have long been identified as the key to overcoming this barrier, yet no one has successfully produced them at the necessary quality — UNTIL NOW.